38 min listen
Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
ratings:
Length:
32 minutes
Released:
Nov 17, 2023
Format:
Podcast episode
Description
What strategies are you using to individualize treatment of HR+/HER2- early breast cancer? Credit available for this activity expires: 11/17/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998210?ecd=bdc_podcast_libsyn_mscpedu
Released:
Nov 17, 2023
Format:
Podcast episode
Titles in the series (100)
A Detective Journey for Nephrologists: Practical Approaches to Differential Diagnosis of Rare Kidney Diseases: How able are you to distinguish C3G from IC-MPGN by looking at patients suspected of glomerular diseases presenting with overlapping signs and symptoms? Credit available for this activity expires: 6/19/24 Earn Credit / Learning Objectives &... by Keeping Current CME